EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects

Kai Huang, Shaohong Yin, Weiguo Huang, Lairong Ding, Wei Qin, Zhenzhong Qian, Ying Ding, Linling Que iD, Yunfei Shi, Jinxia Gao, Yi Zhao

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70197 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Kai Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Na…. Hauptthemen laut MEDLINE: Budesonide, Glucocorticoids, Metered Dose Inhalers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lunan Better Pharmaceutical Co., LTD.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Budesonide is a first‐line inhaled glucocorticoid (ICS) for asthma treatment in adults and children. The purpose of this study was to compare the pharmacokinetics and assess the bioequivalence between two budesonide pressurized metered‐dose inhalers (pMDIs, 200 μg/actuation × 1 actuation) in healthy Chinese subjects. The study was conducted in 32 healthy Chinese subjects using a single‐center, randomized, open‐label, four‐period and crossover design with a 3‐day washout between periods. Blood samples were collected up to 16 h post‐dose. Plasma concentrations of budesonide were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Reference‐scaled average bioequivalence (RSABE) or average bioequivalence (ABE) method was applied to evaluate the bioequivalence, on the basis of the within‐subject standard deviation ( S WR ) of the reference product (Budiair), and the safety was also assessed. Eventually, 31 subjects completed this study. For the maximum concentration ( C max ) (within‐subject standard deviation, S WR ≥ 0.294), the RSABE method showed a geometric mean ratio (GMR) of 97.13% with a 95% upper confidence bound of < 0. For the area under plasma concentration‐time curve from time zero to the last measurable concentration (AUC 0−t ) and the area under plasma concentration‐time curve extrapolated to infinity (AUC 0−∞ ) ( S WR < 0.294), ABE yielded GMRs of 104.81% and 104.61%, with 90% confidence intervals (CIs) of 99.98%–109.86% and 99.81%–109.63%, respectively. All adverse events (AEs) were mild to moderate and transient, with no serious adverse events (SAEs) reported. The two budesonide pMDIs (200 μg) were bioequivalent and well tolerated in healthy Chinese subjects. Trial Registration: Chinese Clinical Trial Registry, Registration No. CTR20244600; ClinicalTrials.gov identifier: NCT06924190

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BudesonideGlucocorticoidsMetered Dose InhalersAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, InhalationArea Under CurveChinaCross-Over StudiesHealthy VolunteersTandem Mass SpectrometryTherapeutic EquivalencyEast Asian People

Stichwörter der Autor:innen

bioequivalencebudesonidepharmacokineticspressurized metered dose inhaler

Substanzen

BudesonideGlucocorticoids

Autor:innen und Institutionen

  • Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.
  • Lunan Better Pharmaceutical Co. LTD, Shandong, China.

ORCID-Profile: Linling Que

Förderung

  • Lunan Better Pharmaceutical Co., LTD

Zitieren

APA

Huang, K., Yin, S., Huang, W., Ding, L., Qin, W., Qian, Z., Ding, Y., Que, L., Shi, Y., Gao, J., & Zhao, Y. (2025). A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70197

Vancouver

Huang K, Yin S, Huang W, Ding L, Qin W, Qian Z, et al. A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70197

BibTeX
@article{Huang2025,
  author = {Huang, Kai and Yin, Shaohong and Huang, Weiguo and Ding, Lairong and Qin, Wei and Qian, Zhenzhong and Ding, Ying and Que, Linling and Shi, Yunfei and Gao, Jinxia and Zhao, Yi},
  title = {A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70197}
}
Kostenlos starten →